Poly(ADP-Ribose) Polymerase Inhibitor Development: Promising Strategies to Move Beyond Approved Indications.
JCO precision oncology（2024）
摘要
Biomarker-based patient selection and rational combinations show promise in expanding the use of PARP inhibitors.
更多查看译文
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要